BIIB Latest Press Releases

-- June 4, 2026 --

BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm Business Wire 8:58 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PRNewswire 10:08 AM

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy Globe Newswire 7:30 AM

EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus Globe Newswire 1:00 AM

-- June 3, 2026 --

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses Globe Newswire 7:30 AM

-- June 2, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB Globe Newswire 5:07 PM

-- June 1, 2026 --

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus Globe Newswire 1:30 AM

-- May 28, 2026 --

Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire 4:01 PM

-- May 26, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB Globe Newswire 4:50 PM

-- May 22, 2026 --

Biogen Inc. (BIIB) Securities Fraud Investigation - Levi & Korsinsky PRNewswire 9:00 AM

-- May 21, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB PRNewswire 6:40 PM

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease Globe Newswire 6:00 PM

-- May 20, 2026 --

Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB) Globe Newswire 9:00 AM

-- May 19, 2026 --

BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud Business Wire 4:00 PM

-- May 18, 2026 --

BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations PRNewswire 9:00 AM

-- May 15, 2026 --

Biogen Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Biogen Inc. (BIIB) PRNewswire 7:02 PM

-- May 14, 2026 --

Biogen Completes Acquisition of Apellis Pharmaceuticals Globe Newswire 8:35 AM

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease Globe Newswire 6:59 AM

-- May 8, 2026 --

Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease PRNewswire 2:30 AM

Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease Globe Newswire 2:30 AM

-- May 7, 2026 --

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600 PRNewswire 6:02 PM

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- May 5, 2026 --

Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent Business Wire 6:37 AM

-- April 30, 2026 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates Business Wire 4:01 PM

-- April 20, 2026 --

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS Business Wire 3:56 PM

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region PRNewswire 7:30 AM

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region Globe Newswire 7:30 AM

-- April 8, 2026 --

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire 4:01 PM

-- April 7, 2026 --

Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Business Wire 4:01 PM

-- March 31, 2026 --

Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS Business Wire 10:08 PM

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology Globe Newswire 6:59 AM

-- March 30, 2026 --

FDA Approves New High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Globe Newswire 7:30 AM

-- March 28, 2026 --

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity Globe Newswire 3:00 PM

-- March 20, 2026 --

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 PRNewswire 12:05 PM

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI (lecanemab-irmb) in the United States Presented at AD/PD 2026 Globe Newswire 12:05 PM

-- March 19, 2026 --

Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action Globe Newswire 8:00 AM

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting Globe Newswire 7:30 AM

-- March 12, 2026 --

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Avantor, Inc. (AVTR), Baxter International Inc. (BAX), Biogen Inc. (BIIB), and CarMax, Inc. (KMX) Globe Newswire 10:29 AM

-- March 11, 2026 --

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy Globe Newswire 8:00 AM

-- March 5, 2026 --

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences Globe Newswire 7:30 AM

-- March 4, 2026 --

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Business Wire 5:06 PM

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome Globe Newswire 5:05 PM

-- February 24, 2026 --

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference Business Wire 4:01 PM

-- February 11, 2026 --

Biogen Announces Board Chair Transition Globe Newswire 5:00 PM

-- February 8, 2026 --

Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China Globe Newswire 9:00 PM

-- February 5, 2026 --

-- February 4, 2026 --

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Business Wire 4:01 PM

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy Globe Newswire 7:30 AM

-- January 28, 2026 --

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options Globe Newswire 7:30 AM

-- January 25, 2026 --

FDA Accepts LEQEMBI IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review PRNewswire 6:30 PM

FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review Globe Newswire 6:30 PM

-- January 12, 2026 --

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Globe Newswire 11:05 AM

-- January 11, 2026 --

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome Business Wire 2:00 PM

-- January 5, 2026 --

Biologics License Application for Subcutaneous Formulation of "LEQEMBI" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China Globe Newswire 8:00 PM